Monograph Details
|
|
Respiratory Tract
> Asthma/COPD
|
|
AEROBID |
| Manufacturer |
|
Forest Laboratories |
| Legal Classification |
|
Rx
|
| Pharmacological Class |
|
Steroid. |
| Generic Name |
|
Flunisolide 250 micrograms/inh; metered dose inhaler. |
| Also |
|
• AEROBID-M
|
| Indications |
|
Maintenance treatment of asthma as prophylactic therapy. Asthma requiring systemic corticosteroid therapy, to reduce need for systemic corticosteroids. |
| Children |
|
<6 years: not recommended. 6–15 years: 2 inh twice daily. Rinse mouth after use. |
| Adults |
|
Initially 2 inh twice daily; max 8 inh/day. Rinse mouth after use. |
| Contraindications |
|
Not for primary treatment of acute attack. |
| Precautions |
|
Infections. If exposed to measles or chickenpox, consider anti-infective prophylactic therapy. If adrenal insufficiency exists following systemic corticosteroid therapy, replacement with inhaled corticosteroids may exacerbate symptoms of adrenal insufficiency (eg, lassitude). Monitor for growth suppression in children. Monitor for hypercorticism and HPA axis suppression (if occur discontinue gradually). Transferring from systemic corticosteroids: see literature. If needed, may use aerosol bronchodilator first. Pregnancy (Cat.C). Nursing mothers. |
| Adverse Reactions |
|
GI upset, oral candidiasis, headache, upper respiratory infection, pharyngitis, GI distress, dizziness. |
| How Supplied |
|
Both—7 g (100 inh) |
| Additional Resources |
|
• Related Prescribing Note |
|
|
|
|
